Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more) Sego Intersects 100 M of 0.626 gpt Gold, Including 24.37 M of 0.958 gpt Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.


NDAQ:ALLR - Post by User

Allarity Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1384)
•••
  • IseneschalX
Post by Iseneschalon Dec 05, 2023 10:42am
84 Views
Post# 35768972

ALLR ...lets see if this Maggot is different?

ALLR ...lets see if this Maggot is different?
10 mins after the open the sh price went sideways for about 25 mis then dropped....It will be interesting if this repeats right now??

Watching
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities